342 related articles for article (PubMed ID: 19466903)
1. Atrial-selective sodium channel block for the treatment of atrial fibrillation.
Burashnikov A; Antzelevitch C
Expert Opin Emerg Drugs; 2009 Jun; 14(2):233-49. PubMed ID: 19466903
[TBL] [Abstract][Full Text] [Related]
2. Atrial-selective sodium channel blockers: do they exist?
Burashnikov A; Antzelevitch C
J Cardiovasc Pharmacol; 2008 Aug; 52(2):121-8. PubMed ID: 18670368
[TBL] [Abstract][Full Text] [Related]
3. In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.
Aguilar-Shardonofsky M; Vigmond EJ; Nattel S; Comtois P
Biophys J; 2012 Mar; 102(5):951-60. PubMed ID: 22404917
[TBL] [Abstract][Full Text] [Related]
4. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Ann N Y Acad Sci; 2008 Mar; 1123():105-12. PubMed ID: 18375582
[TBL] [Abstract][Full Text] [Related]
5. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
[TBL] [Abstract][Full Text] [Related]
6. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
[TBL] [Abstract][Full Text] [Related]
7. Effect of Na+-channel blockade on the three-dimensional substrate of atrial fibrillation in a model of endo-epicardial dissociation and transmural conduction.
Gharaviri A; Verheule S; Eckstein J; Potse M; Krause R; Auricchio A; Kuijpers NHL; Schotten U
Europace; 2018 Nov; 20(suppl_3):iii69-iii76. PubMed ID: 30476060
[TBL] [Abstract][Full Text] [Related]
8. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.
Burashnikov A; Barajas-Martinez H; Hu D; Robinson VM; Grunnet M; Antzelevitch C
J Cardiovasc Pharmacol; 2020 Aug; 76(2):164-172. PubMed ID: 32453071
[TBL] [Abstract][Full Text] [Related]
9. Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.
Burashnikov A; Belardinelli L; Antzelevitch C
J Pharmacol Exp Ther; 2012 Jan; 340(1):161-8. PubMed ID: 22005044
[TBL] [Abstract][Full Text] [Related]
10. Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.
Burashnikov A; Petroski A; Hu D; Barajas-Martinez H; Antzelevitch C
Heart Rhythm; 2012 Jan; 9(1):125-31. PubMed ID: 21884675
[TBL] [Abstract][Full Text] [Related]
11. AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog.
Burashnikov A; Zygmunt AC; Di Diego JM; Linhardt G; Carlsson L; Antzelevitch C
J Cardiovasc Pharmacol; 2010 Jul; 56(1):80-90. PubMed ID: 20386458
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.
Burashnikov A; Belardinelli L; Antzelevitch C
Heart Rhythm; 2015 Apr; 12(4):836-44. PubMed ID: 25546810
[TBL] [Abstract][Full Text] [Related]
13. The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy.
Aguilar M; Nattel S
J Cardiovasc Pharmacol; 2015 Nov; 66(5):432-40. PubMed ID: 25923324
[TBL] [Abstract][Full Text] [Related]
14. [Non-channel drugs to prevent atrial fibrillation].
Fazekas T; Liszkai G
Orv Hetil; 2005 Nov; 146(45):2287-94. PubMed ID: 16304807
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiological effects of ranolazine in a goat model of lone atrial fibrillation.
Opačić D; van Hunnik A; Zeemering S; Dhalla A; Belardinelli L; Schotten U; Verheule S
Heart Rhythm; 2021 Apr; 18(4):615-622. PubMed ID: 33232809
[TBL] [Abstract][Full Text] [Related]
16. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
Regan CP; Kiss L; Stump GL; McIntyre CJ; Beshore DC; Liverton NJ; Dinsmore CJ; Lynch JJ
J Pharmacol Exp Ther; 2008 Jan; 324(1):322-30. PubMed ID: 17967939
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches for pharmacological management of atrial fibrillation.
Ehrlich JR; Nattel S
Drugs; 2009; 69(7):757-74. PubMed ID: 19441867
[TBL] [Abstract][Full Text] [Related]
18. New antiarrhythmic drugs for atrial flutter and atrial fibrillation: a conceptual breakthrough at last?
Cosío FG; Delpón E
Circulation; 2002 Jan; 105(3):276-8. PubMed ID: 11804977
[No Abstract] [Full Text] [Related]
19. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.
Antzelevitch C; Burashnikov A
Ann N Y Acad Sci; 2010 Feb; 1188():78-86. PubMed ID: 20201889
[TBL] [Abstract][Full Text] [Related]
20. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.
Li D; Sun H; Levesque P
Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):64-75. PubMed ID: 19149545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
